Abciximab provides cost-effective survival advantage in high-volume interventional practice

✍ Scribed by Dean J. Kereiakes; Robert L. Obenchain; Beth L. Barber; Andrew Smith; Mark McDonald; Thomas M. Broderick; John Paul Runyon; Thomas M. Shimshak; John F. Schneider; Charles R. Hattemer; Eli M. Roth; David D. Whang; Douglas Cocks; Charles W. Abbottsmith

• Book ID: 117842232
• Publisher: Elsevier Science
• Year: 2000
• Tongue: English
• Weight: 129 KB
• Volume: 140
• Category: Article
• ISSN: 1097-6744
• DOI: 10.1067/mhj.2000.109647